AlphAIAlphAI — Financial news for AI agents
stocktitan.net$CGON

Planned CG Oncology (NASDAQ: CGON) insider sale totals 826 shares

CG Oncology (CGON) officer Ambaw Bellete plans to sell 826 shares, worth $61,950, on September 11, 2026, following a stock option exercise. The sale will be executed through Morgan Stanley Smith Barney LLC. The filing also lists Bellete's prior sales, including 100,000 shares on August 19, 2026, for $7,954,105.

Original reporting
stocktitan.net
Published Sep 11, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 12, 2026, 2:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CGON
Neutral
high confidence
Mentioned
$CGON
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CGONNeutralLow
01

Why it matters

The disclosed sale adds a modest amount of CGON shares to the market, unlikely to move price.

02

Market read

Routine insider transaction with limited trading relevance.

03

What to watch

Potential future larger sales or cumulative insider activity not captured in this single filing.

Relevance 4/10Novelty 3/10Timing: Sep 11, 2026 (sale date)

Background

Form 144 filings disclose when insiders can sell restricted shares, providing transparency on potential supply.

Company-level read

Ticker impact

$CGONNeutralHigh confidence
Context

Form 144 filing shows officer Ambaw Bellete will sell 826 CGON shares (~$62k) on Sep 11, 2026, indicating a modest insider sell.

Expected impact

No material move expected; price may stay flat.

Evidence & confidence

The transaction size is trivial relative to market cap and typical daily volume.

Market effects

Sector

None; biotech sector not affected by a micro‑sale.

Regional

No regional impact.

Global

Insignificant.

Counterpoint

What could challenge this read

If the insider is offloading shares, it could hint at undisclosed concerns, but the amount is too small to infer.

Key entities

  • Officer
    Ambaw Bellete

    CG Oncology officer planning the share sale.

Read at source← All news

Related articles

$CGONHigh

Why is CG Oncology stock surging today?

CG Oncology (CGON) stock rose 19.7% after Q3 2026 results showed a smaller-than-expected loss of $0.64 per share and revenue of $1.60M, both beating estimates. The company announced upcoming clinical trial data and a BLA submission, with a cash position of $984.5M. Analysts have a 'Moderate Buy' rating and $87.50 average price target.

investing.com
$CGONMed

CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates

CG Oncology, Inc. (CGON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates • PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026 • BOND-003 Coho

SEC EDGAR 8-K
$CGONMed

CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

CG Oncology (NASDAQ: CGON) reported Q2 2026 results for the quarter ended June 30, 2026, with net loss of $79.1 million, or $0.90 per share. Cash, cash equivalents and marketable securities were about $1.0 billion, funding operations through 2029. The company said PIVOT-006 topline data are expected soon, and a BLA for HR BCG-unresponsive NMIBC is expected in Q4 2026.

finanznachrichten.de
$CGONMed

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

CG Oncology, Inc. (CGON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates • PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-term • BLA completion for HR BCG-u

SEC EDGAR 8-K
$NVDAHigh

International Business: Nvidia CEO Jensen Huang steps down in big blow to AI boom

Nvidia CEO Jensen Huang is stepping down, with CFO Colette Kress taking over as interim CEO. Huang, Nvidia's co-founder and fourth-largest investor, will also exit the board. Nvidia shares fell over 10% in premarket trading. The company faces uncertainty as Huang was a key figure in its AI success. Michael Feldman of ClearBridge Investments noted concerns about execution risks without Huang's leadership.

gdnonline.com